a
Cardiovascular and cerebrovascular diseases continue to
threaten the lives of humans, especially those of middle-aged adults and the
elderly. Thrombosis is the main cause of death due to cardiovascular diseases,
which includes chronic thrombosis and results in cerebral ischemia, hypoxia,
tissue softening, and necrosis. This study investigated the anti-thrombotic
potential of Lactobacillus plantarum KFY05 (LP-KFY05) and its underlying
mechanism via the NF-κB pathway in a murine carrageenan-induced thrombosis
model. Biochemical assays, microscopic examination, qPCR, and western blotting
were employed to analyse serum and tissue parameters, while faecal microbial
abundance was assessed to determine changes in gut microbiota composition.
Results demonstrated that LP-KFY05 significantly reduced tail blackening in
thrombotic mice (n=10 per group), prolonged activated partial thromboplastin
time (APTT), and decreased thrombin time (TT), fibrinogen (FIB) level, and
prothrombin time (PT). Furthermore, LP-KFY05 treatment lowered serum and renal
tissue concentrations of tumour necrosis factor-alpha (TNF-α), interleukin-6
(IL-6), and interleukin-1 beta (IL-1β). Histopathological analysis via
hematoxylin and eosin staining revealed that LP-KFY05 alleviated renal tissue
injury and tail vein thrombosis. qPCR results indicated that LP-KFY05
downregulated mRNA expression of NF-κB p65, IL-6, TNF-α, and interferon-γ
(IFN-γ) in renal tissues, as well as NF-κB p65, intercellular adhesion
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin
in tail vein vascular tissues. Western blot analysis confirmed the
downregulation of NF-κB protein expression in both renal and tail vein tissues.
Additionally, LP-KFY05 increased the abundances of Bacteroidetes,
Lactobacillus, and Bifidobacterium, while reducing the abundance of Firmicutes.
In conclusion, LP-KFY05 effectively mitigates inflammation and inhibits
thrombosis in mice, with high-dose LP-KFY05 exhibiting the most pronounced
effects, comparable to those of the positive control drug dipyridamole. However,
this study was conducted in a murine model, and further clinical investigations
are necessary to confirm the efficacy and safety of LP-KFY05 in humans.
Author(s) Details
Shi Zeng
Department of Neurosurgery, People’s Hospital of Chongqing Banan District,
Chongqing, China.
Ruokun Yi
Chongqing Collaborative Innovation Center for Functional Food, Chongqing
Engineering Research Center of Functional Food, Chongqing Engineering
Laboratory for Research and Development of Functional Food, Chongqing
University of Education, Chongqing, China.
Fang Tan
Department of Public Health, Our Lady of Fatima University, Valenzuela,
Philippines.
Peng Sun
Chongqing Collaborative Innovation Center for Functional Food, Chongqing
Engineering Research Center of Functional Food, Chongqing Engineering
Laboratory for Research and Development of Functional Food, Chongqing
University of Education, Chongqing, China.
Qiang Cheng
Department of Neurosurgery, People’s Hospital of Chongqing Banan District,
Chongqing, China.
Xin Zhao
Chongqing Collaborative Innovation Center for Functional Food, Chongqing
Engineering Research Center of Functional Food, Chongqing Engineering
Laboratory for Research and Development of
Functional Food, Chongqing University of Education, Chongqing, China.
Please see the book here :- https://doi.org/10.9734/bpi/mono/978-81-998509-9-6/CH6
No comments:
Post a Comment